Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Wednesday's Bonus Article A Fresh IPO That Long-Term Investors Shouldn't IgnoreWritten by Jordan Chussler. Date Posted: 1/14/2026. 
What You Need to Know - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful often offer considerable short-term upside potential. Of course, they also carry substantial downside risk. But even conservative investors shouldn't dismiss every recent IPO; some newly public companies may merit a place in buy-and-hold portfolios. What If Washington Declared That: YOUR Money ISN'T Actually Yours?
Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property.
What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want. Get your free guide now by clicking here >> For one biotechnology company in the healthcare sector that just went public, that could be the case. Last Year's IPO Success Stories Last year illustrates why some IPOs deserve a look even from investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its roughly 359% gain before it reached 30 days on the Nasdaq, but longer-term holders are still enjoying strong returns. Not all IPOs are small startups. Medline (NASDAQ: MDLN), a medical products and services provider founded in 1966, debuted publicly in December 2025 and already has a market cap exceeding $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its packaged bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it immediately relevant for income investors. After its IPO and with shares beginning to trade on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, reducing damage to healthy tissue compared with some conventional treatments. Industry consultancy Grand View Research estimates the global nuclear medicine market was nearly $18 billion in 2024 and could reach almost $35 billion by 2030—a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant contributor—an important factor for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding and policy shifts slowed listings from the healthcare sector in 2025. Aktis Oncology, which began trading on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest sums for a biotech listing in recent memory. The offering generated $318 million in proceeds and the company now has a market cap of about $3.34 billion. According to the company's prospectus, Aktis' executive team includes drug development, approval and commercialization experts, and members of management have participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting significant attention from Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares as part of the offering. That investment builds on a partnership formed in 2024 in which Eli Lilly provided $60 million in cash, made an equity investment in Aktis and agreed to a collaboration on tumor-targeting radiopharmaceuticals with potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing is notable: at roughly $1.01 trillion, it is one of the largest pharmaceutical companies by market cap, and its net income rose nearly 109% year-over-year from 2023 to 2024. That momentum is likely to continue when Eli Lilly reports Q4 and full-year 2025 financial results on Feb. 5. Between its equity stake and the recent $100 million in AKTS shares, the maker of Zepbound now has a meaningful financial interest in Aktis Oncology's success.
| 
